Category Archives: Business

UN Council Adopts Resolution to Launch Investigation of Rights Abuses in Myanmar

The United Nations Human Rights Council on Friday said it will dispatch an independent, international fact-finding mission to investigate alleged recent human rights violations by the Myanmar military and security forces in western Myanmar's Rakhine state.

The mission will be looking into reports of murder, rape, torture, and arson by security forces in Rohingya Muslim communities in the northern part of the state during a four-month crackdown that began last October following deadly attacks on border guard posts blamed on Rohingya militants.

About 1,000 people died during the operations and more than 77,000 Rohingya fled, mostly to neighboring Bangladesh where they are living in refugee camps.

Myanmar disassociated itself from the draft of the European Union-backed resolution, and specifically from the call for the urgent dispatch of a fact-finding mission, according to a statement by the U.N. Human Rights Council (OHCHR).

The country said it was committed to finding a sustainable solution to the situation in Rakhine state, and that based on the findings and recommendations of a national investigation commission and an advisory commission for Myanmar would put in place a long-term peace-building plan for Rakhine state.

Presidential spokesman Zaw Htay told RFA's Myanmar Service that it was not fair for the council to send a separate mission to look into the human rights abuse allegations, given the country's national-level commission led by Vice President Myint Swe and an Rakhine advisory commission headed by former U.N. chief Kofi Annan.

It is totally unfair and counter to international practice that other countries have decided to send a separate mission to investigate violations when we haven't completed our own investigations, he said.

Their action shows a lack of respect to the host country.

He added that the Myanmar government would continue promoting and defending human rights as recommended by the United Nations and is implementing the country's human rights policy.

We'll take action against the perpetrators, he said in a reference to anyone found to have committed human rights abuses during the crackdown in Rakhine.

Zaw Htay said the country has to deal with other factors related to the recent crisis in Rakhine State that began last October along with important issues such as achieving national peace and reconciliation after decades of ethnic separatist civil wars.

At this juncture, this U.N. resolution will not help our efforts to resolve these issues, he said. Therefore, we cannot agree with the resolution, and we have dissociated ourselves from it. We cannot accept this resolution.

Institutional discrimination

The resolution also states that Myanmar should continue to address systematic and institutionalized discrimination against the Rohingya and other ethnic and religious minorities in the country.

Zaw Htay said that Myanmar's Human Rights Commission will issue a report soon and that national leaders will continue to work for a long-lasting solution to the problems in Rakhine state.

The state is home to more than 1.1 million Rohingya who are denied citizenship and access to basic services because Myanmar considers them illegal immigrants from Bangladesh.

Communal violence with ethnic Rakhine Buddhists in 2012 left more than 200 people dead and displaced about 140,000 Rohingya who were forced to live in appalling conditions in internally displaced persons camps.

The independent mission, which will be appointed by the council's president, will submit an update on its work during the body's autumn session.

China disassociated itself from the draft resolution, saying that the international community should look at the progress Myanmar has made in human rights and respect the country's sovereignty by creating a favorable environment for the parties to resolve their differences through dialogue.

Rights groups applauded the move, with New York-based Human Rights Watch calling it a step toward preventing future abuses and brining justice for victims in Myanmar.

The Human Rights Council's authorization of an international fact-finding mission is crucial for ensuring that allegations of serious human rights abuses in Burma are thoroughly examined by experts, and to ensure that those responsible will ultimately be held accountable, said John Fisher, HRW's director in Geneva, Switzerland.

Burma's government should cooperate fully with the mission, including by providing unfettered access to all affected areas, he said.

East Asia-based Fortify Rights called the move a landmark resolution and urged the Myanmar government to fully cooperate with it.

We commend the Human Rights Council for this initiative. It's long overdue, said Matthew Smith, the group's chief executive officer. While this mission isn't a silver bullet, it's a welcome and positive move toward prevention and accountability.

Relations with the military

The resolution comes as Myanmar's de facto leader, Aung San Suu Kyi, tries to forge peace in a country wracked by fighting between ethnic armed groups and Myanmar's powerful military, in addition to addressing the problems in Rakhine state.

Aung San Suu Kyi's efforts to improve the government's relationship with the country's military is based on the need for reconciliation, rather than a struggle for power, Win Htein, spokesman of the ruling National League for Democracy (NLD), told RFA on Friday.

Aung San Suu Kyi's efforts to forge a better relationship with the military, including military commander-in-chief Senior General Min Aung Hlaing, is headed towards reconciliation and not meant to gain more power, he said.

He noted that the country's 2008 constitution, written by the army, gives control of the ministries of defense, home affairs, and border affairs to the military whether we like it or not.

Military officials also are appointed to a quarter of the seats in parliament.

Analysts say the military's independence from control by elected politicians helps explain why Aung San Suu Kyi has not been able to respond effectively to widespread and numerous reports of army atrocities in Rakhine. The Nobel Peace laureate has been criticized internationally over the Rakhine bloodshed.

Though Aung San Suu Kyi has indicated that she would like to see the constitution amended to decrease the power of the military in government affairs, she has striven to maintain good relations with Min Aung Hlaing and the generals who head up the three ministries, Win Htein said.

The previous military junta that ruled the country for 50 years kept Aung San Suu Kyi under house arrest for 15 years when she was head of the NLD, which was then the main opposition party.

As proof of improving ties between Aung San Suu Kyi and Min Aung Hlaing, Win Htein pointed to the general's attendance at Martyrs' Day last July 19, which had been boycotted by the generals in the past.

The military chief also attended an interfaith religious ceremony held at Aug San Suu Kyi's residence in Yangon that day.

These are the fruits of Aung San Suu Kyi's efforts to forge better ties with General Min Aung Hlaing, which are required for national reconciliation in the future, said Win Htein.

It's a very incorrect assumption by local and foreign observers that Aung San Suu Kyi cannot overcome the military's influence, he said.

Copyright (copyright) 1998-2016, RFA. Used with the permission of Radio Free Asia, 2025 M St. NW, Suite 300, Washington DC 20036

Call for Entries Issued for Fourteenth International Business Awards

Early-Bird Entry Deadline Is 12 April

FAIRFAX, Va., March 22, 2017 (GLOBE NEWSWIRE) — The Stevie® Awards have issued the call for entries for The 14th Annual International Business Awards, the world’s premier business awards competition, which attracts nominations from organizations in more than 60 nations and territories each year.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8540ffb4-6337-429d-9f7c-3574f68f49c3

All individuals and organizations worldwide — public and private, for-profit and non-profit, large and small — may submit nominations to The International Business Awards. The early-bird entry deadline, with reduced entry fees, is 12 April. The final entry deadline is 10 May, and late entries will be accepted through 14 June with payment of a late fee. Entry details are available at www.StevieAwards.com/IBA.

An international judging panel of more than 150 executives will determine the Stevie Award winners. Results will be announced 10 August. Stevie Award winners will be presented their awards at a gala banquet at the W Hotel in Barcelona, Spain on 21 October.

The International Business Awards recognize achievement in every facet of the workplace. Categories include:

Stevie Award winners in the 2016 IBAs included ABS-CBN Corporation (Philippines), BSES Yamuna Power Limited (India), Clickky (Ukraine), Dogus Group (Turkey), Dubai Statistics Center (United Arab Emirates), Forter (USA), Foundation Telefónica  (Spain), Freelancer.com (Australia), Itaú Unibanco Holding S.A. (Brazil), KEPCO Nuclear Fuel Company (South Korea), Mondelez International (United Kingdom), Ooredoo (Qatar), PJSC Aeroflot – Russian Airlines  (Russia), Polystar (Sweden), PRIZM (Hong Kong), QLess, Inc. (USA), RheinBrücke IT Consulting (Germany), Roshan (Afghanistan), SABC Pension Fund (South Africa), SUNNY SIDE UP, Inc. (Japan), Telkom Indonesia (Indonesia) and TELUS International (Canada), among many others.

About the Stevie Awards

Stevie Awards are conferred in seven programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, the Stevie Awards for Sales & Customer Service and the Stevie Awards for Great Employers. Stevie Awards competitions receive more than 10,000 entries each year from organizations in more than 60 nations. The Stevies recognize outstanding performances in the workplace worldwide. Learn more at http://www.StevieAwards.com.

Contact:
Maggie Gallagher
+1 (703) 547-8389
[email protected]

Call for Entries Issued for Fourteenth International Business Awards

Early-Bird Entry Deadline Is 12 April

FAIRFAX, Va., March 22, 2017 (GLOBE NEWSWIRE) — The Stevie® Awards have issued the call for entries for The 14th Annual International Business Awards, the world’s premier business awards competition, which attracts nominations from organizations in more than 60 nations and territories each year.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8540ffb4-6337-429d-9f7c-3574f68f49c3

All individuals and organizations worldwide — public and private, for-profit and non-profit, large and small — may submit nominations to The International Business Awards. The early-bird entry deadline, with reduced entry fees, is 12 April. The final entry deadline is 10 May, and late entries will be accepted through 14 June with payment of a late fee. Entry details are available at www.StevieAwards.com/IBA.

An international judging panel of more than 150 executives will determine the Stevie Award winners. Results will be announced 10 August. Stevie Award winners will be presented their awards at a gala banquet at the W Hotel in Barcelona, Spain on 21 October.

The International Business Awards recognize achievement in every facet of the workplace. Categories include:

Stevie Award winners in the 2016 IBAs included ABS-CBN Corporation (Philippines), BSES Yamuna Power Limited (India), Clickky (Ukraine), Dogus Group (Turkey), Dubai Statistics Center (United Arab Emirates), Forter (USA), Foundation Telefónica  (Spain), Freelancer.com (Australia), Itaú Unibanco Holding S.A. (Brazil), KEPCO Nuclear Fuel Company (South Korea), Mondelez International (United Kingdom), Ooredoo (Qatar), PJSC Aeroflot – Russian Airlines  (Russia), Polystar (Sweden), PRIZM (Hong Kong), QLess, Inc. (USA), RheinBrücke IT Consulting (Germany), Roshan (Afghanistan), SABC Pension Fund (South Africa), SUNNY SIDE UP, Inc. (Japan), Telkom Indonesia (Indonesia) and TELUS International (Canada), among many others.

About the Stevie Awards

Stevie Awards are conferred in seven programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, the Stevie Awards for Sales & Customer Service and the Stevie Awards for Great Employers. Stevie Awards competitions receive more than 10,000 entries each year from organizations in more than 60 nations. The Stevies recognize outstanding performances in the workplace worldwide. Learn more at http://www.StevieAwards.com.

Contact:
Maggie Gallagher
+1 (703) 547-8389
[email protected]

ASEAN Looks to ‘Framework’ on South China Sea Security

BANGKOK � Southeast Asia, seeking a long term agreement to settle disputes in the South China Sea, faces new challenges as China moves to extend its regional influence with plans for a scientific station on islets close to the Philippines.

The concerns come as analysts say the United States' Asia policy is currently focused on rising tensions on the Korean Peninsula.

Philippine President, Rodrigo Duterte, currently chairman of the Association of South East Asian Nations (ASEAN), this week held talks with regional partners Myanmar and Thailand.

Freedom of navigation

Following talks in Bangkok with Thailand's Prime Minister Prayut Chan-o-cha, the countries agreed to promote freedom of navigation in the South China Sea as a core value in securing peace and prosperity in the region.

Maintaining peace, stability and security as well as respecting freedom of navigation and over-flight in the South China Sea, are in the interests of all countries, within an outside the region, as they are fundamental conditions for growth, development and prosperity, Duterte said.

Thai analyst Kavi Chongkittavorn said Thailand and the Philippines hope to have a code of conduct framework completed by July, to then add nuts and bolts to the agreement.

Code of conduct

ASEAN's long time goal has been to press ahead with implementation of a 2002 declaration on the conduct of parties in the South China Sea or code of conduct. But Beijing has long resisted completing a legally binding code, leading to divisions within ASEAN.

However, China is to host a meeting of ASEAN in May on the Code of Conduct framework, with diplomats hoping on progress towards a legally-binding document to manage regional disputes.

Environmental monitoring station

But the talks in Bangkok follow official Chinese media reports saying Beijing may be preparing to install an environmental monitoring station at Scarborough Shoal, which sits inside the Philippines' 200 nautical mile exclusive economic zone. The Chinese foreign ministry denied those reports Wednesday.

In 2016 China pressed ahead with consolidating its military position on the Spratly Islands, including runways on Fiery Cross, Subi and Mischief Reefs, reinforced hangers to accommodate fighter jets as well as other defenses, improving port facilities and installing radar.

The U.S., which has carried out military exercises near Scarborough Shoal, strongly opposed any Chinese construction there under former President Obama.

US attention now focused on North Korea

But analysts say President Donald Trump's administration is preoccupied with tensions on the Korean peninsula, where North Korea has been testing rockets.

Carl Thayer, a defense analyst at Australia's University of New South Wales, said Washington's attention has shifted from the South China Sea issue.

The South China Sea has been lost. It's just not on the radar. It is there but it's like a pot that's been put on the burner and the heat has been turned down. Everybody else is looking at not moving a fire on the main cooking pot � and that's North Korea, Thayer said.

China is strengthening claims

Analysts say uncertainties over the U.S. policy towards the South China Sea and a comprehensive strategy for Asia generally has enabled China to adopt a stronger position to its claims to the region.

James Chin, director of the Asia Institute at the University of Tasmania, said the uncertainties over the U.S. policy have led to disappointment within ASEAN.

Now they think it's going to be a stalemate and people are thinking that the Americans only worry about North Korea and the North Korean crisis. They don't worry about the South China Sea, Chin said.

Now all bets are off. The problem with this approach it that the longer you leave the South China Sea alone, it means to give more time to the Chinese to keep building military bases, he said.

China nears de-facto control

Once China builds on reclaimed land on the Scarborough Shoal, it means they will have de-facto control of the South China Sea.

Thayer said a Chinese airfield on the Shoal would be strategically significant completing a triangle linking Woody Island in the Parcels, the occupied features in the Spratly Islands, giving China the ability to monitor all aircraft and surface ships passing over or through the South China Sea.

[But] they will allow freedom of navigation because China is essentially a trading nation. So they will not disturb the freedom of navigation � so that's the positive, said Chin.

China claims much of the South China Sea through the so-called nine dash line that extends near Malaysia, Brunei, the Philippines and Vietnam.

Source: Voice of America

RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease

  • A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional countries
  • The open-label extension study (the MAP US2 study) is intended to assess the safety and efficacy of RHB-104 in patients who have completed 26 weeks of treatment in the ongoing MAP US Phase III study and remain with active Crohn’s disease (CDAI>150); these patients have the opportunity to receive treatment with RHB-104 for a 52-week period in the open-label extension study
  • The MAP US2 open-label extension study is considered separate from the ongoing MAP US Phase III study and data collected will be supplemental to the MAP US study data
  • A second independent DSMB meeting for the MAP US Phase III study is expected in mid-2017, including an interim efficacy analysis and an evaluation of an option for early stop for success for overwhelming efficacy
  • RHB-104 is a proprietary, orally-administered, potentially groundbreaking antibiotic combination therapy with potent intracellular, antimycobacterial and anti-inflammatory properties

TEL-AVIV, Israel, March 21, 2017 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced dosing of the first patient in the open-label extension study to the Phase III study with RHB-104 for the treatment of Crohn’s Disease (the MAP US study).

RHB-104 is a proprietary, orally-administered, potentially groundbreaking antibiotic combination therapy with potent intracellular, antimycobacterial and anti-inflammatory properties.

The MAP US study is a randomized, double-blind, placebo-controlled first Phase III study, intended to evaluate the safety and efficacy of RHB-104 in patients with moderately to severely-active Crohn’s disease (defined as Crohn’s Disease Activity Index (CDAI) between 220 and 450). To date, 266 patients out of a planned total of 410 patients have been enrolled in the study, which is being conducted in up to 150 clinical sites in the U.S, Canada, Europe, Israel, Australia and New Zealand. A long-term population pharmacokinetic (pop-PK) study is also ongoing as part of the MAP US study. Additional studies will be required to support a U.S. New Drug Application (NDA) for RHB-104.

The open-label extension study (the MAP US2 study) is intended to assess the safety and efficacy of RHB-104 in patients who have completed 26 weeks of treatment in the ongoing MAP US Phase III study and remain with active Crohn’s disease (CDAI>150) at week 26, the MAP US study’s primary endpoint. These patients have the opportunity to receive treatment with RHB-104 for a 52-week period in the open-label extension study. This study is considered separate from the ongoing MAP US Phase III study, and data collected will be supplemental to the MAP US study data. The open-label extension study’s primary endpoint is disease remission at week 16, defined as CDAI less than 150. The open-label extension MAP US2 study is planned to enroll approximately 100 subjects in up to 150 clinical sites in the U.S., Canada, Europe, Israel, Australia and New Zealand. Additional open-label studies with RHB-104 for Crohn’s disease are being planned by RedHill, to provide further supportive clinical data for potential future marketing applications.

A second independent Data and Safety Monitoring Board (DSMB) meeting of the MAP US Phase III study, expected in mid-2017, will include an interim efficacy analysis and will evaluate the option for an early stop for success for overwhelming efficacy, according to a pre-specified statistical significance threshold. Assuming the study is not stopped for success or inefficacy following the DSMB meeting in mid-2017, completion of recruitment for the MAP US study is expected by the end of 2017. In December 2016, a first, pre-planned independent DSMB meeting reviewed safety data from the ongoing MAP US study and provided a unanimous recommendation to continue the study as planned.

The development of RHB-104 is based on increasing evidence supporting the hypothesis that Crohn’s disease, and potentially other autoimmune diseases, are related to Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients. The development of RHB-104 is consistent with the growing awareness of the possibility that a bacterially-induced dysregulated immune system may contribute to the pathogenesis of various autoimmune diseases of unknown etiology.

The MAP US Phase III study is registered on www.ClinicalTrials.gov, a web-based service of the U.S. National Institutes of Health, which provides access to information on publicly and privately supported clinical studies.

About RHB-104:
Currently in a first Phase III study for the treatment of Crohn’s disease (the MAP US study), RHB-104 is a proprietary, orally-administered, potentially groundbreaking oral antibiotic combination therapy, with potent intracellular, antimycobacterial and anti-inflammatory properties. RHB-104 is based on increasing evidence supporting the hypothesis that Crohn’s disease is caused by Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients. Clinical trials conducted with earlier formulations of RHB-104 include an Australian Phase III study conducted by Pharmacia/Pfizer. RedHill has conducted several supportive studies with the current formulation of RHB-104 and a long-term population pharmacokinetic (pop-PK) study is ongoing as part of the Phase III MAP US study. Additionally, an open-label extension study (the MAP US2 study) is ongoing to assess the safety and efficacy of RHB-104 in patients who have completed 26 weeks of treatment in the ongoing Phase III MAP US study and remain with active Crohn’s disease (CDAI>150) at week 26. RHB-104 is covered by several issued and pending patents. RedHill has also completed a Phase IIa, proof-of-concept clinical study, evaluating RHB-104 as an add-on therapy to interferon beta-1a in patients treated for relapsing-remitting multiple sclerosis (the CEASE MS study). Top-line final results from the CEASE MS study suggest meaningful positive safety and clinical signals upon 24 weeks of treatment with RHB-104 as an add-on therapy, thereby supporting further clinical development.

About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is a specialty biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill has a U.S. co-promotion agreement with Concordia for Donnatal®, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis. RedHill’s clinical-stage pipeline includes: (i) RHB-105 an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 an oral combination therapy for the treatment of Crohn’s disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis and QIDP status for nontuberculous mycobacteria (NTM) infections; (iii) BEKINDA® (RHB-102) a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA® (ABC294640) a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON – a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors and (vii) RIZAPORT® (RHB-103) – an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015. More information about the Company is available at: www.redhillbio.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to successfully market Donnatal®, (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; and (xii) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing; (xiii) competitive companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on February 23, 2017. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.

Company contact:
Adi Frish
Senior VP Business Development & 
Licensing 
RedHill Biopharma
+972-54-6543-112
[email protected]

IR contact (U.S.): 
Marcy Nanus
Senior Vice President
The Trout Group
+1-646-378-2927
[email protected]